GT Molecular, Inc.
Fort Collins, CO
- UEI
- DKH3J319XJL6
- CAGE
- 8AAJ2
- Primary NAICS
- 541380 Testing Laboratories and Services
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 225 Commerce Dr, Fort Collins, CO 80524, USA
- Website
- gtmolecular.com
- Founded
- 2018
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $311,684 |
| FY2025 | $299,386 |
| FY2024 | $468,209 |
| FY2023 | $62,504 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $311,684 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| National wastewater surveillance system multi-pathogen assay development, optimization, validation, and support | CDC Pittsburgh | $1,029,779 | |
| Nwss multi-assay panel development | CDC Pittsburgh | $297,004 |
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Eastern Research Group Inc. | 68HERC23F0152 | $65,040 |
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Improving influenza vaccines through wastewater-based macro-scale strain surveillance | National Institute of Allergy and Infectious Diseases (NIH) | $256,575 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Godx Inc. | Madison, WI | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Biobot Analytics Inc. | Cambridge, MA | 541380 Testing Laboratories and Services |
| G L S | South San Francisco, CA | 541990 All Other Professional, Scientific, and Technical Services |
| Tetracore, Inc. | Rockville, MD | 334519 Other Measuring and Controlling Device Manufacturing |
| Instadiagnostics Inc. | Philadelphia, PA | 339112 Surgical and Medical Instrument Manufacturing |
About the company
GT Molecular, Inc., doing business as GT Molecular LLC, is a minority-owned, self-certified small disadvantaged business specializing in advanced molecular diagnostics and surveillance technologies. The company focuses on providing digital PCR-based assay development, optimization, and validation services to support public health initiatives, particularly in the areas of wastewater surveillance for pathogens and antimicrobial resistance. GT Molecular has positioned itself as a key player in the development of multi-pathogen assay panels compatible with various digital PCR platforms, offering crucial services to federal agencies engaged in disease monitoring and control efforts.
As a prime contractor, GT Molecular has been awarded significant federal contracts by the Centers for Disease Control and Prevention (CDC) to support the National Wastewater Surveillance System (NWSS). In September 2024, the company secured a $1,665,445 firm-fixed-price contract, set aside for small businesses, to develop, optimize, and validate a portfolio of sensitive and robust molecular testing assays for multiple pathogens, antimicrobial resistance, and vector targets in wastewater. This contract includes a 12-month base period with four 12-month option periods. Previously, in September 2022, GT Molecular was awarded a $297,003.74 sole-source purchase order to develop a multi-pathogen, digital PCR assay panel compatible with both Qiagen Qiacuity and BioRad QX digital PCR platforms. The company has also provided analytical services as a subcontractor to Eastern Research Group Inc., supporting field sampling activities under a contract with an unspecified federal agency. These contracts demonstrate GT Molecular's expertise in developing specialized molecular testing solutions for federal public health surveillance programs.
In the realm of federal grants, GT Molecular has been involved in innovative research aimed at improving influenza vaccines through wastewater-based macro-scale strain surveillance. In February 2022, the company received a project grant (R43AI167462) from the National Institute of Allergy and Infectious Diseases to develop a novel approach for monitoring influenza and SARS-CoV-2 in community wastewater. This research project, scheduled to run until July 2022, focused on expanding GT Molecular's existing SARS-CoV-2 wastewater monitoring capabilities to include influenza prevalence monitoring and genomic characterization of circulating strains. The goal was to provide a more comprehensive dataset for international surveillance programs to use in their yearly strain inclusion decision-making for vaccine development, potentially improving vaccine efficacy for both influenza and SARS-CoV-2. This grant work showcases GT Molecular's commitment to advancing public health through innovative molecular surveillance techniques and its ability to contribute to cutting-edge research in viral monitoring and vaccine development.
SBA capabilities narrative
GT Molecular was created to develop new molecular detection technology for cancer research and harmful pathogen detection. The company brings deep experience in molecular genetics, assay technology development, and clinical medicine. Since the beginning of the pandemic, GT Molecular has focused these powerful tools on the detection of SARS-CoV-2 in wastewater to support communities around the country with their monitoring programs.
Quick answers
Is GT Molecular, Inc. registered in SAM.gov?
Yes. GT Molecular, Inc.'s SAM.gov registration is active through August 28, 2027.
How much has GT Molecular, Inc. received in federal contracts?
Federal contracts obligated $299,386 to GT Molecular, Inc. in fiscal year 2025 and $1,141,783 in fiscal years 2023 through 2027.
How does GT Molecular, Inc. rank among federal contractors?
GT Molecular, Inc. ranked #57 in PSC B529 in FY2025.
What is GT Molecular, Inc.'s most recent federal award?
GT Molecular, Inc.'s most recent federal contract award is National wastewater surveillance system multi-pathogen assay development, optimization, validation, and support (75D30124C19209), from CDC Pittsburgh, on September 3, 2024.
On GovTribe
See GT Molecular, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors